matrices between distinct brain regions. Initially, the consortium will analyze average group differences in these measures between OCD patients and controls, and subsequently use machine‐learning methods to determine whether rs‐fMRI can provide a biomarker for OCD. Furthermore, the same methods will be used in order predict CBT outcome at the group and individual patient level. We hope that this endeavor will provide a biomarker for treatment outcome that generalizes to different sites, and thereby paves the way towards personalized treatment for OCD. In the future, we hope to extend rs‐fMRI meta‐analysis in ENIGMA‐OCD to task‐based fMRI, focusing on frequently used paradigms such as emotional processing, response inhibition (and other executive tasks), and decision‐making.
